This protocol covers the management of tubulointerstitial nephritis and uveitis syndrome (TINU) in patients presenting with anterior uveitis — a recognised ocular manifestation of this condition that requires direct, targeted treatment.
The patient has anterior uveitis in the context of TINU syndrome. This ocular involvement is the defining feature of this protocol's patient population.
First-line management in this setting involves a topical corticosteroid approach directed at the eye. The complete structured regimen — including full sequencing, decision points, and monitoring — is available in the protocol below.
The primary clinical goal is response of ocular inflammation to topical corticosteroid therapy.
DOI: 10.1097/ICU.0b013e3283318f9a
In the acute phase, around 1/3 of patients with TINU who have anterior uveitis will respond to topical corticosteroids, whereas 2/3 will require systemic corticosteroids (median duration of treatment is 2.5 months).
Ocular inflammation and renal function respond promptly to corticosteroid treatment during active disease, but maintaining quiescence in the eye can be more difficult than in the kidney.